UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2013
Biota Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-35285 |
|
59-1212264 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
| |||
|
2500 Northwinds Parkway, Suite 100 Alpharetta, GA |
|
30009 | ||
|
(Address of principal executive offices) |
|
(Zip Code) | ||
Registrant’s telephone number, including area code: (678) 221-3351
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
(b) On September 10, 2013, Peter Cook tendered his resignation from the Board of Directors of Biota Pharmaceuticals, Inc. (the “Company”), effective immediately. There was no disagreement between Mr. Cook and the Company on any matter relating to the Company’s operations, policies or practices relative to his resignation. In connection therewith, Mr. Cook also resigned from the Board of Directors and as an officer of all subsidiaries and affiliates of the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| |
|
|
|
|
|
Biota Pharmaceuticals, Inc. | |||
|
|
|
| |||||
|
Date: September 13, 2013 |
|
|
|
/s/ Russell H. Plumb | |||
|
|
|
|
|
Name: |
|
Russell H. Plumb | |
|
|
|
|
|
Title: |
|
President and Chief Executive Officer (Duly Authorized Officer) | |